乐普生物-B:营收大幅增长 多款核心产品进入研发晚期

华创证券
09 Apr

事项:乐普生物发布2024 年业绩,2024 年公司实现营业收入3.68 亿元(+63.21%),其中:1)普特利单抗销售收入达3.00 亿元,较2023 年销售额的1.01 亿元增长约3 倍,2)BD 收入0.22 亿元,来自CMG901 里程碑付款,3)CDMO 服务收入0.46 亿元;年内亏损4.24 亿元。2024 年末,公司现金收支实现基本持平,货币资金余额4.01 亿元。评论:ADC ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10